The molecular interaction of sulfonylureas with β-cell ATP-sensitive K+-channels

https://doi.org/10.1016/0168-8227(95)01076-PGet rights and content

Abstract

The molecular interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor was investigated by kinetic and steady state binding as well as photoaffinity labeling. The novel sulfonylurea, glimepiride, exhibits a significantly higher exchange rate with the sulfonylurea receptor but a 2.5-3 fold lower binding affinity compared to glibenclamide. [3H]Glimepiride was specifically incorporated into a 65-kDa polypeptide under conditions which led to predominant labeling of a 140-kDa protein by [3H]glibenclamide. Labeling of the 140-kDa protein by [3H]glibenclamide was inhibited by unlabeled glimepiride and, vice versa, glibenclamide inhibited labeling of the 65-kDa protein by [3H]glimepiride. The 65-kDa protein was also specifically photolabeled by the sulfonylurea [125I]35623, whereas an 4-azidobenzoyl derivative of glibenclamide, N3-[3H]33055, exclusively labeled a 33-kDa protein. Solubilization of β-cell tumor membranes led to a shift of specific [3H]glibenclamide-binding from the 140-kDa to the 65-kDa protein, exclusively and to an increased labeling of the 65-kDa protein by [3H]glimepiride. The labeling of a unique protein is in agreement with similar kd-values for binding to the sulfonylurea receptor measured for both sulfonylureas upon solubilization of β-cell membranes. Photoaffinity labeling of intact cultured β-cells led also to labeling of a 140-kDa protein by [3H]glibenclamide and of a 65-kDa protein by [3H]glimepiride. These studies suggest that the β-cell sulfonylurea receptor consists of at least two protein subunits of Mr 140 000 and 65000 which bind sulfonylureas of different structure with different binding affinities and kinetic parameters. Furthermore, the exchange rate of a sulfonylurea determines the insulin releasing activity in vitro more closely than the binding affinity.

References (0)

Cited by (40)

  • Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies

    2021, Experimental Neurology
    Citation Excerpt :

    BIIB093 is an intravenous (IV) formulation of glibenclamide (also known as glyburide). Glibenclamide is a sulfonylurea class of drugs that has been in clinical use as an oral hypoglycemic agent for the treatment of type 2 diabetes since 1969 (Feldman, 1985; Kurland et al., 2013; Marble, 1971) as it promotes the release of insulin by blocking pancreatic KATP [sulfonylurea receptor 1 (Sur1)-Kir6.2] channels (Kramer et al., 1995; Panten et al., 1996). Glibenclamide has received renewed attention in the last decade due to its neuroprotective effect in CNS injury, where its principal target is the transient receptor potential melastatin 4 (Trpm4), a non-slecetive cation channel that has been shown to be associated with Sur1 to form the Sur1-Trpm4 channels (Simard et al., 2006; Woo et al., 2013).

  • Counterregulatory responses to hypoglycemia differ between glimepiride and glyburide in non diabetic individuals

    2015, Metabolism: Clinical and Experimental
    Citation Excerpt :

    Furthermore, Kramer et al. [32,33] have reported that individual sulfonylureas can interact with differing components of KATP channels. The same group has also demonstrated that glimepiride had a 3–4 fold lower binding affinity as compared to glyburide [32,33]. Although this study cannot identify the precise molecular mechanisms responsible for the differing physiologic effects of glimepiride and glyburide, the above studies certainly point to a plausible physiologic basis for our findings.

  • The role of glimepiride in the effective management of Type 2 diabetes

    2004, Journal of Diabetes and its Complications
View all citing articles on Scopus
View full text